Jim Cramer on Gilead Sciences: “I’d Hold On to It”

Gilead Sciences, Inc. (NASDAQ:GILD) was among the stocks Jim Cramer reviewed on Mad Money while discussing the recent market rotation. During the lightning round, a caller asked for Cramer’s take on the stock, and he replied:

You know, I like what Daniel O’Day is doing. I always bump into him at the JPMorgan conference. I think he’s a smart guy, and the company’s good. I’d hold on to it. They’ve got some good franchises.

A stock market data. Photo by AlphaTradeZone on Pexels

Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company that develops treatments for major medical conditions like HIV, hepatitis, and COVID-19. The company also uses advanced cell therapies for cancer treatment, and it maintains several partnerships to discover new small-molecule and antibody medicines.

While we acknowledge the risk and potential of GILD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GILD and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.